Hunan Er Kang Pharmaceutical - Asset Resilience Ratio
Hunan Er Kang Pharmaceutical (300267) has an Asset Resilience Ratio of 1.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hunan Er Kang Pharmaceutical current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Hunan Er Kang Pharmaceutical's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Hunan Er Kang Pharmaceutical assets under control.
Liquid Assets Composition Over Time
This chart breaks down Hunan Er Kang Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Hunan Er Kang Pharmaceutical total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥60.00 Million | 1.19% |
| Total Liquid Assets | CN¥60.00 Million | 1.19% |
Asset Resilience Insights
- Limited Liquidity: Hunan Er Kang Pharmaceutical maintains only 1.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hunan Er Kang Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Hunan Er Kang Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Hunan Er Kang Pharmaceutical (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Hunan Er Kang Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.31% | CN¥120.00 Million ≈ $17.56 Million |
CN¥5.20 Billion ≈ $760.88 Million |
+2.31pp |
| 2023-12-31 | 0.00% | CN¥118.60K ≈ $17.35K |
CN¥5.48 Billion ≈ $801.76 Million |
-1.95pp |
| 2022-12-31 | 1.95% | CN¥114.12 Million ≈ $16.70 Million |
CN¥5.86 Billion ≈ $856.87 Million |
+1.87pp |
| 2020-12-31 | 0.08% | CN¥5.30 Million ≈ $775.97K |
CN¥6.55 Billion ≈ $958.00 Million |
-2.00pp |
| 2015-12-31 | 2.08% | CN¥100.00 Million ≈ $14.63 Million |
CN¥4.80 Billion ≈ $702.59 Million |
-- |
About Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for i… Read more